Ro
Funding History
| Series B · 04/2019 | $500M |
|---|---|
| Series C · 07/2020 | $1.5B |
| Series D · 03/2021 | $5.0B |
| Series E (Additional Financing) · 02/2022 | $7.0B |
About
Ro operates as a full-stack healthcare company, combining telehealth consultations, a network of pharmacies and pharmacy fulfillment partners, at-home lab testing, and in-person care into a single patient experience across men's health, women's health, weight loss, and primary/preventive care.
- CEO
- Zachariah Reitano
- Founded
- 2017
- Headquarters
- New York, NY
- Employees
- 700+ (reported 2022; more recent third-party estimates cite 201-500)
- Website
- Ro.co
Overview
Ro (formerly Roman Health Ventures, doing business as Ro) is a New York-based direct-to-patient healthcare company operating a vertically integrated telehealth platform spanning online consultations, an in-house pharmacy network, at-home diagnostics, and in-person care.
Founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Rob Schutz, Ro initially launched as Roman, a men's health platform for erectile dysfunction and hair loss, before expanding into women's health (Rory), at-home fertility and lab testing (through its 2021 acquisition of Modern Fertility), and its Ro Body program covering GLP-1 weight-loss medications, insurance navigation, lab work, and coaching.
Ro has raised over $1 billion in venture funding, reaching a peak reported valuation of $7 billion in a February 2022 financing led by ShawSpring Partners, and has built partnerships with pharmaceutical manufacturers including Eli Lilly and Novo Nordisk to distribute GLP-1 medications such as Zepbound and Wegovy directly to patients.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.